HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 03, March 2017 – Get to Know TCM       » Chinese Scientists in Rice Breakthrough       » Leading Regional Medical Technology Trade Associations Reinforce their Commitment to Evidence-based Healthcare       » New Study Finds Extensive Use of Fluorinated Chemicals in Fast Food Wrap       » What Doesn't Kill You Makes You Stronger       » Life Under Pressure       » Understanding the Genetics of Human Height      
BIOBOARD - JAPAN
Daiichi Sankyo initiates Phase 3 ENSURE-AF study, investigating patients with atrial fibrillation undergoing cardioversion
Daiichi Sankyo, a Japanese pharmaceutical company, has started enrolling patients into the ENSURE-AF multinational phase 3 study. ENSURE-AF is a Prospective, Randomized, Open-Label, Blinded Endpont evaluation (PROBE), parallel group study, evaluating the efficacy and safety of once-daily edoxaban for the prevention of stroke, systemic embolic event, myocardial infarction and cardiovascular mortality versus enoxaparin/warfarin in patients with NVAF undergoing electrical cardioversion. More than 2,200 patients are expected to be enrolled in ENSURE-AF at approximately 250 clinical sites across North America and Europe.

"Due to the risk of thromboembolism, clinical guidelines recommend anticoagulation before and after cardioversion in patients with atrial fibrillation," said Andreas Goette, MD, Chief Physician, St. Vincenz-Hospital Paderborn, Germany, Department of Cardiology and Intensive Care Medicine and member of the European Heart Rhythm Association's International Affairs Committee with responsibility for Japan. "This trial will provide us with insights on whether edoxaban can be a viable treatment option for non-valvular atrial fibrillation patients undergoing cardioversion."

Atrial fibrillation (AF) is a condition in which the heartbeat is rapid and irregular, and can potentially lead to a stroke. AF is a common condition, affecting approximately 2.3–3.4% of people in developed nations. Compared to those without AF, people with the arrhythmia have a 3–5 times higher risk of stroke. Strokes due to AF are nearly twice as likely to be fatal than strokes in patients without AF at 30 days and have poorer prognosis than non-AF related strokes, with a 50% increased risk of remaining disabled at three months.

"This is a very exciting study as this will be the largest planned clinical trial to evaluate a novel oral anticoagulant with the current standard of care in patients undergoing cardioversion," said Gregory YH Lip, Professor of Cardiovascular Medicine, University of Birmingham, UK. "The novel oral anticoagulants offer the possibility of efficacy, safety and convenience for the peri-cardioversion management of patients with atrial fibrillation."

Click here for the complete issue.

NEWS CRUNCH  
news Philip Morris International and British American Tobacco receive award from PETA science group for AOP developments
news 6th Asia-Pacific Breast Cancer Summit to take place in Hong Kong
news MIT Hacking Medicine Robotics in Singapore!
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetics Technology
May:
The Piece of Your Mind - Brain Health/Science
June:
Women & Men's Health
July:
Food Science & Technology
August:
Eye Care/ Eye Health
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy